Literature DB >> 10224130

Regulation of NF-kappaB RelA phosphorylation and transcriptional activity by p21(ras) and protein kinase Czeta in primary endothelial cells.

J Anrather1, V Csizmadia, M P Soares, H Winkler.   

Abstract

The activity of the transcription factor NF-kappaB is thought to be regulated mainly through cytoplasmic retention by IkappaB molecules. Here we present evidence of a second mechanism of regulation acting on NF-kappaB after release from IkappaB. In endothelial cells this mechanism involves phosphorylation of the RelA subunit of NF-kappaB through a pathway involving activation of protein kinase Czeta (PKCzeta) and p21(ras). We show that transcriptional activity of RelA is dependent on phosphorylation of the N-terminal Rel homology domain but not the C-terminal transactivation domain. Inhibition of phosphorylation by dominant negative mutants of PKCzeta or p21(ras) results in loss of RelA transcriptional activity without interfering with DNA binding. Raf/MEK, small GTPases, phosphatidylinositol 3-kinase, and stress-activated protein kinase pathways are not involved in this mechanism of regulation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10224130     DOI: 10.1074/jbc.274.19.13594

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  39 in total

1.  Protein kinase C-delta regulates thrombin-induced ICAM-1 gene expression in endothelial cells via activation of p38 mitogen-activated protein kinase.

Authors:  A Rahman; K N Anwar; S Uddin; N Xu; R D Ye; L C Platanias; A B Malik
Journal:  Mol Cell Biol       Date:  2001-08       Impact factor: 4.272

Review 2.  Intestinal epithelial responses to enteric pathogens: effects on the tight junction barrier, ion transport, and inflammation.

Authors:  J Berkes; V K Viswanathan; S D Savkovic; G Hecht
Journal:  Gut       Date:  2003-03       Impact factor: 23.059

3.  Mutant human cells with constitutive activation of NF-kappaB.

Authors:  Swati S Sathe; Nywana Sizemore; Xiaoxia Li; Kalpa Vithalani; Mairead Commane; Shannon M Swiatkowski; George R Stark
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-22       Impact factor: 11.205

4.  Activation of IKK/NF-κB provokes renal inflammatory responses in guanylyl cyclase/natriuretic peptide receptor-A gene-knockout mice.

Authors:  Subhankar Das; Ramu Periyasamy; Kailash N Pandey
Journal:  Physiol Genomics       Date:  2012-02-07       Impact factor: 3.107

5.  Monoubiquitination of nuclear RelA negatively regulates NF-κB activity independent of proteasomal degradation.

Authors:  Karin Hochrainer; Gianfranco Racchumi; Sheng Zhang; Costantino Iadecola; Josef Anrather
Journal:  Cell Mol Life Sci       Date:  2012-01-20       Impact factor: 9.261

6.  Citrobacter rodentium-induced NF-kappaB activation in hyperproliferating colonic epithelia: role of p65 (Ser536) phosphorylation.

Authors:  Yu Wang; Guang-Sheng Xiang; Famourou Kourouma; Shahid Umar
Journal:  Br J Pharmacol       Date:  2006-06-05       Impact factor: 8.739

7.  Nuclear factor-kappaB activation and postischemic inflammation are suppressed in CD36-null mice after middle cerebral artery occlusion.

Authors:  Alexander Kunz; Takato Abe; Karin Hochrainer; Munehisa Shimamura; Josef Anrather; Gianfranco Racchumi; Ping Zhou; Costantino Iadecola
Journal:  J Neurosci       Date:  2008-02-13       Impact factor: 6.167

8.  Activation of NF-kappaB is essential for hepatocyte growth factor-mediated proliferation and tubulogenesis.

Authors:  Markus Müller; Alessandro Morotti; Carola Ponzetto
Journal:  Mol Cell Biol       Date:  2002-02       Impact factor: 4.272

9.  Inhibition by pentoxifylline of TNF-alpha-stimulated fractalkine production in vascular smooth muscle cells: evidence for mediation by NF-kappa B down-regulation.

Authors:  Yung-Ming Chen; Chao-Jung Tu; Kung-Yu Hung; Kwan-Dun Wu; Tun-Jun Tsai; Bor-Shen Hsieh
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

Review 10.  Nf-kappa B, chemokine gene transcription and tumour growth.

Authors:  Ann Richmond
Journal:  Nat Rev Immunol       Date:  2002-09       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.